Tesamorelin
Also known as: Egrifta
Association with increased mortality in patients with respiratory failure or trauma
Pharmacokinetics
- Half-life
- 2 hours
- Time to peak
- 30 min
- Bioavailability
- 80%
Administration
- Primary routes
- SubQ
- Category
- Growth Hormone Secretagogues
Safety Flags
- Contraindicated in cancer history
Storage
- · Requires refrigeration (2–8°C)
- · Temperature sensitive — minimise room-temp exposure
Used in 0 outcome protocols
Tesamorelin is in the registry but not yet referenced by any of the 25 outcome protocols. It may appear in user-built custom stacks in the Lab.
Simulate Tesamorelin
Pinned.life runs a 1-compartment Bateman pharmacokinetic simulation against 38 peptides in real time. Build a stack, see serum-level curves, get warned about peak overlaps and drug-peptide interactions.